X

Trial Profile

Phase I Evaluation of Sodium Stibogluconate [VQD 001; VioQuest Pharmaceuticals] in Combination With Interferon alpha-2b for Solid Tumors, Lymphoma or Myeloma.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interferon alpha-2b (Primary) ; Sodium stibogluconate (Primary)
Indications Lymphoma; Multiple myeloma; Solid tumours
Focus Adverse reactions; Therapeutic Use

Most Recent Events

21 Nov 2009 Planned number of patients changed from 24 to 54 as reported by M.D. Anderson Cancer Center record.
30 Jun 2009 Trial phase changed from I/II to I and additional lead trial centre as reported by ClinicalTrials.gov.
11 Jun 2008 Status changed from in progress to completed as reported by VioQuest Pharmaceuticals.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com